oral squamous cell carcinoma
Conditions
Interventions
Docetaxel (60 mg/m2) was administered intravenously for 1 h on day1. After completion of the docetaxel infusion, nedaplatin (100 mg/m2) was administered intravenously for another hour followed by 1,00
Sponsors
Chubu research group on oral cancer
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) age between 20 and 75 years (patients aged >76 years were allowed if major organs functions was preserved), (2) Eastern Cooperative Oncology Group performance status (PS) score of 2 or less (3) adequate bone marrow function (4) adequate hepatic function (5) adequate renal function (6) Written informed consent
Exclusion criteria
Exclusion criteria: Patients were excluded if they had active infections, active second malignancy, severe heart diseases, interstitial pneumonia or lung fibrosis, severe pleural effusion or pericardial effusion that required drainage, fever more than or equal to 38 C, symptomatic brain metastasis, severe psychological disease, and possible pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical and histopathological effect of induction chemotherapy with docetaxel and nedaplatin for resectable oral squamous cell carcinoma | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of induction chemotherapy with docetaxel and nedaplatin for resectable oral squamous cell carcinoma | — |
Countries
Japan
Outcome results
None listed